Asset: Potent and selective oral PARP1 small-molecule inhibitor
Development Stage: PCC nomination
Indication: Breast cancer, prostate cancer and multiple solid tumors
Key Asset Highlights:
- Exhibits high selectivity and potent inhibitory activity against PARP1, a core therapeutic target governing DNA damage repair, with minimized off-target effects on other PARP family members.
- Induces robust synthetic lethal anti-tumor effects in HR-deficient solid tumors, delivering superior single-agent efficacy in preclinical models of breast and prostate cancer compared with conventional PARP inhibitors.
- Effectively reverses acquired drug resistance to clinical PARP inhibitors, demonstrating prominent anti-tumor potency in drug-resistant tumor models with unmet clinical needs.
- Shows strong synergistic anti-tumor activity in combination with chemotherapy and targeted agents, enabling diversified oral combination therapeutic regimens for expanded clinical application scenarios.
- Possesses optimal oral pharmacokinetic properties and a broad safety window, supporting convenient oral administration and long-term clinical treatment in outpatient settings.
- Backed by a solid and comprehensive intellectual property portfolio, securing exclusive and stable global development and commercialization rights for future clinical advancement and market deployment.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
